Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone Receptor Positive Advanced Breast Cancer

Condition:   Breast Neoplasm Female Interventions:   Drug: CDK 4/6 inhibitor;   Drug: Non-Steroidal Aromatase Inhibitor;   Drug: Fulvestrant Sponsor:   Borstkanker Onderzoek Groep Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

(Oxford University Press USA) A new study in the Journal of the National Cancer Institute finds that black women are more likely to skip hormone therapy treatments, also known as endocrine therapy, for breast cancer.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
The MONALEESA-3 trial marks an important step forward for endocrine therapies for advanced breast cancer, argues Lidia Schapira.Medscape Oncology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Viewpoint Source Type: news
Source: OncoTargets and Therapy - Category: Cancer & Oncology Tags: OncoTargets and Therapy Source Type: research
AbstractEstrogen is a steroid hormone that has critical roles in reproductive development, bone homeostasis, cardiovascular remodeling and brain functions. However, estrogen also promotes mammary, ovarian and endometrial tumorigenesis. Estrogen antagonists and drugs that reduce estrogen biosynthesis have become highly successful therapeutic agents for breast cancer patients. The effects of estrogen are largely mediated by estrogen receptor (ER) α and ERβ, which are members of the nuclear receptor superfamily of transcription factors. The mechanisms underlying the aberrant expression of ER in breast cancer and ot...
Source: Experimental Hematology and Oncology - Category: Cancer & Oncology Source Type: research
Publication date: Available online 16 September 2018Source: PathophysiologyAuthor(s): Rabab Ahmed Ahmed Mohammed, Moustafa EzEldien M. Radwan, Bashayer Marzoog Alrufayi, Linah Abdulsamad Qari AbdulazizAbstractBackgroundSome breast carcinomas (BC) of the HER-2 type respond poorly to endocrine therapy, indicating that hormonal receptor (HR) status possibly impacts the biological criteria of this tumor class. The aim of this study was to compare the clinicopathological characteristics of HR-positive and HR-negative tumors occurring in HER-2 and non-HER-2 BC.MethodsTissue microarray sections from 336 primary invasive BC specim...
Source: Pathophysiology - Category: Pathology Source Type: research
Abstract As de novo and acquired resistance to standard first line endocrine therapies is a growing clinical challenge for estrogen receptor-positive (ER+) breast cancer patients, understanding the mechanisms of resistance is critical to develop novel therapeutic strategies to prevent therapeutic resistance and improve patient outcomes. The widespread post-transcriptional regulatory role that microRNAs (miRNAs) can have on various oncogenic pathways has been well-documented. In particular, several miRNAs are reported to suppress ERα expression via direct binding with the 3' UTR of ESR1 mRNA, which can confer...
Source: Biological Procedures Online - Category: Molecular Biology Authors: Tags: Biol Proced Online Source Type: research
Publication date: October 2018Source: Seminars in Cancer Biology, Volume 52, Part 1Author(s): Andrea Nicolini, Paola Ferrari, Michael J. DuffyAbstractFollowing a diagnosis of breast cancer, the most immediate challenges in patient management are the determination of prognosis and identification of the most appropriate adjuvant systemic therapy. Determining prognosis can best be addressed with a combination of traditional clinicopathological prognostic factors, biomarkers such as HER2/neu and specific multigene genes tests. Amongst the best validated prognostic multigene tests are uPA/PAI1, Oncotype DX and MammaPrint. Oncot...
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research
Abstract Macroautophagy/autophagy is vital for intracellular quality control and homeostasis. Therefore, careful regulation of autophagy is very important. In the past 10 years, a number of studies have reported that estrogenic effectors affect autophagy. However, some results, especially those regarding the modulatory effect of 17β-estradiol (E2) on autophagy seem inconsistent. Moreover, several clinical trials are already in place combining both autophagy inducers and autophagy inhibitors with endocrine therapies for breast cancer. Not all patients experience benefit, which further confuses and complicates ...
Source: Autophagy - Category: Cytology Authors: Tags: Autophagy Source Type: research
Authors: Bai XM, Yang W, Zhang ZY, Jiang AN, Wu W, Lee JC, Chen MH, Yan K Abstract OBJECTIVE: To evaluate the long-term efficacy and prognostic factors of ultrasound-guided percutaneous radiofrequency ablation (RFA) for breast cancer liver metastasis (BCLM). METHODS: Between 2000 and 2015, 69 patients who underwent ultrasound-guided percutaneous RFA for BCLM and had regular follow-up examinations were included. All patients had undergone resection of the primary breast cancer and had received chemotherapy, endocrine therapy or both after surgery. The sample included two males and 67 females with an average age ...
Source: International Journal of Hyperthermia - Category: Internal Medicine Tags: Int J Hyperthermia Source Type: research
art M Abstract The prognosis of patients with early stage breast cancer has greatly improved in the past three decades. Following the first adjuvant endocrine therapy and chemotherapy trials, continuous improvements of clinical outcomes have been achieved through intense therapeutic escalation, albeit with increased health-care costs and treatment-related toxicities. In contrast to the advances achieved in surgery or radiotherapy, the identification of the patient subgroups that will derive clinical benefit from therapeutic escalation has proved to be a daunting process hindered by a lack of collaboration between ...
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Tags: Nat Rev Clin Oncol Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Endocrine Therapy | Hormones